| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $245,270 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Matheis Dennis | director | 1 | $245,270 | 0 | $0 | $245,270 |
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for …
Over the last 12 months, insiders at Lucid Diagnostics Inc. have bought $245,270 and sold $0 worth of Lucid Diagnostics Inc. stock.
On average, over the past 5 years, insiders at Lucid Diagnostics Inc. have bought $402,358 and sold $53,408 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Matheis Dennis (director) — $245,270.
The last purchase of 245,000 shares for transaction amount of $245,270 was made by Matheis Dennis (director) on 2026‑05‑20.
| 2026-05-20 | Matheis Dennis | director | 245,000 0.2397% | $1.00 | $245,270 | -3.89% | ||
| 2025-08-20 | Matheis Dennis | director | 100,000 0.0911% | $1.02 | $101,840 | +5.83% | ||
| 2025-05-22 | Matheis Dennis | director | 33,218 0.0304% | $1.32 | $43,795 | -14.29% | ||
| 2025-05-21 | Matheis Dennis | director | 129,684 0.1192% | $1.32 | $171,520 | -14.29% | ||
| 2025-05-20 | Matheis Dennis | director | 187,098 0.1723% | $1.29 | $242,292 | -11.54% | ||
| 2023-09-26 | Sale | Lapidus Stanley | director | 29,747 0.0667% | $1.45 | $43,173 | -31.76% | |
| 2023-09-25 | Sale | Lapidus Stanley | director | 200 0.0005% | $1.43 | $286 | -27.62% | |
| 2023-09-21 | Sale | Lapidus Stanley | director | 100 0.0002% | $1.44 | $144 | -25.00% | |
| 2023-09-20 | Sale | Lapidus Stanley | director | 3,817 0.0087% | $1.45 | $5,531 | -25.17% | |
| 2022-09-20 | Sale | Lapidus Stanley | director | 33,864 0.0916% | $1.70 | $57,683 | -13.29% | |
| 2021-10-18 | PAVmed Inc. | 10 percent owner | 571,428 4.5992% | $14.00 | $8M | -67.86% |
| Matheis Dennis | director | 1033443 0.5412% | $422,678.19 | 5 | 0 | <0.0001% |
| PAVmed Inc. | 10 percent owner | 27927190 14.6255% | $11.42M | 1 | 0 | <0.0001% |
| Increased Positions | 50 | +61.73% | 5M | +15.05% |
| Decreased Positions | 28 | -34.57% | 8M | -23.54% |
| New Positions | 19 | New | 655,701 | New |
| Sold Out Positions | 13 | Sold Out | 7M | Sold Out |
| Total Postitions | 103 | +27.16% | 32M | -8.49% |
| Vanguard Group Inc | $5,067.00 | 3.45% | 4.52M | +396,719 | +9.61% | 2025-09-30 |
| Masters Capital Management Llc | $4,479.00 | 3.05% | 4M | +1M | +46.64% | 2025-09-30 |
| Blackrock, Inc. | $4,110.00 | 2.8% | 3.67M | +50,969 | +1.41% | 2025-09-30 |
| Two Seas Capital Lp | $3,360.00 | 2.29% | 3M | +3M | New | 2025-09-30 |
| Awm Investment Company, Inc. | $3,349.00 | 2.28% | 2.99M | +3M | New | 2025-09-30 |
| Ghisallo Capital Management Llc | $3,315.00 | 2.26% | 2.96M | +3M | New | 2025-09-30 |
| Aberdeen Group Plc | $2,800.00 | 1.91% | 2.5M | +3M | New | 2025-09-30 |
| Geode Capital Management, Llc | $1,875.00 | 1.28% | 1.67M | +96,804 | +6.14% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $1,549.00 | 1.06% | 1.38M | +644,839 | +87.34% | 2025-09-30 |
| Perkins Capital Management Inc | $1,262.00 | 0.86% | 1.13M | +1M | New | 2025-09-30 |